Table 2

Group 1. demographics of participant groups at the first appointment, showing the mean with SD in brackets and range below

HD controls (non-antidopaminergic takers)
(n=466)
HD antidopaminergic takers
(n=466)
Number of visits3 (1)
2–6
3.1 (1)
2–6
Gender (m:f)234:232267:200
ISCED
(educational level)
3.6 (1.2)
1–6
3.5 (1.2)
1–6
Age
(years)
54.6 (9.7)
26–79
54.4 (9.2)
26–79
CAG repeat length43 (2.1)
40–55
43.1 (2.1)
40–55
DBS394.4 (55)
180–573.5
397 (55.2)
180–573.5
TFC score9.9 (2.4)
3–13
9.3 (2.5)
3–13
Time since diagnosis
(years)
3.4 (3.7)
0–22
3.8 (3.7)
0–22
Total motor score UHDRS
Max score 124
28.1 (14.6)
0–81
33.8* (15.5)
0–85
Total chorea score UHDRS
Max score 28
8.2 (4.5)
0–26
9.3* (5.2)
0–28
Irritability
(PBA)
Max score 32
2.5 (3.9)
0–25
3.5* (5.1)
0–28
Depression
(PBA)
Max score 48
4.3 (5.8)
0–36
5.7* (6.7)
0–36
Apathy
(PBA)
Max score 16
2.2 (3.4)
0–16
3.7* (4.4)
0–16
MMSE
Max score 30
26.7 (2.7)
14–30
25.7* (3.3)
11–30
Composite cognitive z-score1.3 (5.3)
−21.7 to 18.9
  • 1.3 (5.8)

  • 32.4–16.7

  • ISCED, The International Standard Classification of Education; CAG, cytosine-adenine-guanine; MMSE, Mini-Mental State Examination.

  • *Indicates a significant difference (p<0.001) when compared with the control non-antidopaminergic medication group.

  • DBS, disease burden score; HD, Huntington’s disease; PBA, problems behavioural assessment; TFC, total functional capacity; UHDRS, Unified Huntington Disease Rating Scale.